Adverse events related to drug-drug interactions in tocilizumab combination therapy: a retrospective analysis and clinical implications - PubMed
4 hours ago
- #Tocilizumab
- #Adverse Events
- #Drug-Drug Interactions
- Tocilizumab (TCZ) is used in autoimmune diseases, often combined with other drugs, but limited evidence exists on its drug-drug interactions (DDIs).
- A retrospective study analyzed AEs related to DDIs between TCZ and DMARDs, glucocorticoids, and NSAIDs using data from the OpenVigil FDA platform.
- Four statistical models identified 824 AEs, with 35.6% significantly correlated with DDIs, showing higher reporting rates than when drugs were used alone.
- Musculoskeletal and connective tissue disorders were the most common AEs for TCZ-DMARD and TCZ-NSAID combinations.
- Specific AEs included anti-CCP positivity, hand deformity, and pemphigus with DMARDs; pemphigus, hand deformity, and pericarditis with glucocorticoids; and anti-CCP positive, rheumatic fever, and duodenal ulcer perforation with NSAIDs.
- Age and sex influenced DDI risks: adults were more susceptible to infusion reactions and joint swelling, while male patients had higher incidences of stomatitis and joint swelling, and female patients were more prone to infusion-related reactions and infections.
- Healthcare providers should monitor for DDI-related AEs, especially decreased treatment efficacy, musculoskeletal, cutaneous, and gastrointestinal events, and serological parameters like CRP and Anti-CCP.